Silent venous thromboembolism before treatment in endometrial cancer and the risk factors by Satoh, T et al.
Silent venous thromboembolism before treatment in endometrial
cancer and the risk factors










1 and H Yoshikawa
1
1Department of Obstetrics and Gynecology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba,
Ibaraki, Japan;
2Cardiovascular Division, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki,
Japan;
3Department of Radiology, Institute of Clinical Medicine, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
Venous thromboembolism (VTE) often occurs after surgery and can even occur before surgery in patients with gynaecological
malignancies. We investigated the incidence of VTE before treatment of endometrial cancer and associated risk factors. Plasma
D-dimer (DD) levels before initial treatment were examined in 171 consecutive patients with endometrial cancer. Venous ultrasound
imaging (VUI) of the lower extremities was performed in patients with DD X1.5mgml
 1, as the negative predictive value of DD for
VTE is extremely high. For patients with deep vein thrombosis (DVT), pulmonary scintigraphy was performed to ascertain the
presence of pulmonary thromboembolism (PTE). Risk factors for VTE were analysed using univariate and multivariate analyses for
171 patients. Of these, 37 patients (21.6%) showed DD X1.5mgml
 1, 17 (9.9%) displayed DVT by VUI and 8 (4.7%) showed PTE
on pulmonary scintigraphy. All patients with VTE were asymptomatic. Univariate analysis for various risk factors revealed older age,
non-endometrioid histology and several variables of advanced disease as significantly associated with VTE before treatment. Obesity,
smoking and diabetes mellitus were not risk factors. Multivariate analysis confirmed extrauterine spread and non-endometrioid
histology as independently and significantly associated with risk of VTE. These data suggest that silent or subclinical VTE occurs before
treatment in at least around 10% of patients with endometrial cancer. Risk factors for VTE before treatment might not be identical to
those after starting treatment.
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Deep vein thrombosis (DVT) and subsequent pulmonary thrombo-
embolism (PTE) represent potentially lethal perioperative compli-
cations associated with major pelvic or abdominal operations
(Turpie et al, 2002). Deep vein thrombosis is known to occur in the
postoperative period or during the course of postoperative therapy
in 9.8–57.1% of patients with endometrial carcinoma (Clarke-
Pearson et al, 1983; Crandon and Koutts, 1983; Gore et al, 1984;
von Tempelhoff et al, 2000). Several guidelines (Greets et al, 2001;
Nicolaides et al, 2001, Committee on Practice Bulletins –
Gynecology, American College of Obstetricians and Gynecologists,
2002) have focused on intra- and postoperative management for
preventing venous thromboembolism (VTE). For the prevention of
postoperative DVT, we usually use elastic stockings during surgery
and intermittent pneumatic compression during and after surgery.
However, if DVT exists before the treatment of endometrial
carcinoma, such preventative measures may be ineffective or
possibly dangerous for lethal PTE.
D-dimer (DD) is a degradation product of fibrin and reflects
fibrin concentration. Although increased plasma DD level is
generally thought to be associated with the presence of DVT, the
positive predictive value of DD is 36–44%. Conversely, the
negative predictive value of DD is 89–100% (Bounameaux et al,
1991; Harrison et al, 1993; Wells et al, 2003; Righini et al, 2006).
We have recently reported that increased DD levels are associated
with the presence of silent VTE before treatment in ovarian cancer
(DD o1.5mgml
 1, 0 of 26 (0%); DD X1.5mgml
 1, 18 of 46 (39%))
(Satoh et al, 2007). A suitable cutoff value for detecting VTE in
patients with ovarian cancer seems to be 1.5mgml
 1, which offers
100% sensitivity and 100% negative predictive value, despite low
specificity (47.2%) and low positive predictive value (38.3%). This
study therefore aimed to clarify the incidence of VTE before





Between January 2004 and December 2007, a total of 171
consecutive patients with histologically confirmed endometrial
carcinoma were enrolled in this study. Two patients who under-
went emergent hysterectomy for vaginal bleeding were not
included. Five patients for whom histological diagnosis was
changed from endometrioid carcinoma to carcinosarcoma after
surgery were likewise excluded from the study. All study protocols
were approved by the institutional review board at University of
Tsukuba Hospital, and all patients provided written informed
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sconsent to participate. Initial treatment was performed in the
Department of Obstetrics and Gynecology at the University of
Tsukuba Hospital. Plasma DD level was measured on the first visit
to our outpatient clinic, 2–5 weeks before the initial treatment of
endometrial cancer. Histology of endometrial biopsies in subjects
was as follows: endometrioid carcinoma, n¼150; adenosquamous
carcinoma, n¼4; serous carcinoma, n¼9; clear cell carcinoma,
n¼6; mucinous carcinoma, n¼1; and undifferentiated carcinoma,
n¼1. After surgery, histological diagnosis was changed to mixed
carcinoma in three patients (endometrioid plus serous carcinoma,
n¼1; serous plus clear carcinoma, n¼2), but diagnosis of the
dominant part in these patients remained unchanged. Inter-
national Federation of Gynecology and Obstetrics (FIGO) stage
was as follows: stage I, n¼101; stage II, n¼18; stage III, n¼32;
and stage IV, n¼20. However, we used presumed stage as
evaluated by imaging studies such as computed tomography (CT)
and magnetic resonance imaging (MRI) to analyse risk factors of
VTE in this study. Presumed stage was as follows: stage I, n¼107;
stage II, n¼13; stage III, n¼29; and stage IV, n¼22. Surgical or
pathological FIGO staging resulted in upstaging in 21 cases and
downstaging in 17 cases. Mean patient age was 58.1 years (range,
19–84) and mean body mass index (BMI) was 25.0kg/m
2 (range,
16.8–43.4).
Measurement of plasma DD level
Peripheral blood samples were collected from all patients before
treatment and DD levels were measured. Blood samples were
drawn from an antecubital vein by atraumatic puncture into
plastic tubes using a two-tube technique, discarding the first 4 to
5ml. Whole blood was anticoagulated by the addition of nine
volumes to one volume of 0.11moll
 1 sodium citrate solution,
then centrifuged at 3000r.p.m. for 10min. Citrated plasma was
then removed and frozen at  201C up to 3 days before assessment.
Plasma DD level was measured using STA-Liatest D-Di latex
(Diagnostica Stago, Asnie ¯res, France) sensitised with anti-DD
mouse monoclonal antibody to induce a latex coagulation reaction,
then turbidity was quantified using a spectrophotometer. The
cutoff value for plasma DD in this method is 0.5mgml
 1.
Detection of DVT
All patients underwent comprehensive imaging studies using CT
and MRI to detect abdominal tumour extension and thrombus in
iliac veins and the inferior vena cava. Venous ultrasound imaging
(VUI) was performed to detect DVT only in patients with elevated
DD level of X1.5mgml
 1. Ultrasonography was performed using
an ATL HDI5000 system (Philips Medical Systems, Bothell, WA,
USA) equipped with a 3–7.5MHz transducer. Power, pulse
repetition frequency and wall thump filter settings were adjusted
for venous vascular studies. Iliac, femoral, great saphenous,
popliteal, peroneal, post-tibial and soleal veins were evaluated
bilaterally. Iliac and femoral veins were assessed in a supine
position and other veins were assessed in an upright position. All
veins were imaged on transverse and long axis views. Venous
lumina were observed while searching for thrombus by manual
compression with transducer and colour Doppler imaging. For the
evaluation of intrapelvic veins, reactions during the Valsalva
manoeuvre were also observed. No reaction during the Valsalva
manoeuvre was considered to represent suspected proximal
venous flow disturbance, and intrapelvic DVT was diagnosed
based on the results of enhanced CT. However, no patients
displayed intrapelvic DVT in this study.
Pulmonary perfusion scintigraphy
All patients with DVT detected by VUI were examined by
pulmonary perfusion scintigraphy using Tc-99 to evaluate the
presence of PTE.
Management of patients with VTE before treatment
Anticoagulant therapy was started using unfractionated heparin
immediately after diagnosis of VTE. Therapy was continued until
initial treatment, comprising surgery or chemotherapy, for all
patients with VTE. We always administered anticoagulant therapy
after surgery in these patients. In addition, one of the following
managements was selected in some patients: placement of an
inferior vena cava filter (IVCF) before upfront surgery; or
neoadjuvant chemotherapy (NAC) followed by surgery.
Inferior vena cava filter placement was used before upfront
surgery to prevent lethal PTE in patients with DVT in proximal
veins, such as iliac and femoral veins or floating DVT in peripheral
veins. Neoadjuvant chemotherapy followed by surgery was selected
for patients with apparent stage III/IV endometrial cancer and
chemosensitive tumour histology, such as serous or endometrioid
type as estimated on biopsy and excessively increased CA125 level.
We administered a paclitaxel and carboplatin (TC) regimen
comprising paclitaxel (175mgm
 2 infused over 43h) and AUC
6 of carboplatin.
We also used pelvic irradiation, chemotherapy using a TC
regimen or sequential chemoradiation therapy (TC regimen
followed by pelvic and/or paraaortic radiation) as postoperative
therapy for high-risk patients with stage Ic-IV endometrial cancer.
For patients with lower DD levels (o1.5mgml
 1) and patients
with higher DD levels (X1.5mgml
 1) but without VTE, compres-
sion stockings and intermittent pneumatic compression were used
during and after surgery to prevent postoperative VTE. Low-
molecular-weight heparin was also administered before and after
surgery in patients with BMI X28kg/m
2 and patients who had
been administered anticoagulative medication due to a past history
of cerebral infarction or atrial fibrillation.
RESULTS
Plasma level of DD and incidence of VTE before treatment
Plasma DD level was above the reference value (0. 5mgml
 1)i n7 4
of 171 patients with endometrial cancer (43.3%). Thirty-seven
(21.6%) patients showed DD X1.5mgml
 1. Subsequent VUI and
PS revealed DVT in 17 patients (9.9%) and PTE in 8 patients
(4.7%) (DVT alone, n¼9; DVT plus PTE, n¼8) before initial
treatment. The most proximal location of DVT in these patients
was the peroneal vein in eight patients, popliteal vein in two
patients and soleal vein in seven patients. Mean DD level in 17
patients with VTE was 7.75mgml
 1 (range, 1.7–21.6). D-dimer
levels were associated with the incidence of VTE (1.5–2.9mgml
 1,
3 out of 16 (13.6%); 3.0–4.5mgml
 1, 3 out of 6 (50.0%); and
44.5mgml
 1, 11 out of 15 (73.3%); P-value for trend¼0.009). All
patients with VTE were asymptomatic when VTE was identified.
As VUI was performed only in patients with DD X1.5mgml
 1,
sensitivity, specificity and negative predictive values were not able
to be evaluated. The positive predictive value of DD using
1.5mgml
 1 as the cutoff level for silent VTE was 46.0% (17/37).
Risk factors for VTE before treatment
Table 1 shows relative risks for VTE according to personal
characteristics, direct invasion, tumour extension, histology and
tumour markers. Study variables determined before initial
treatment were used in this analysis, with tumour extension
(presumed stage) and myometrial invasion from imaging studies,
histology from endometrial biopsy and tumour markers before
treatment. Among these variables, older age, large tumour size in
the uterine cavity, deep myometrial invasion, extrauterine spread,
massive ascites, ovarian metastasis, paraaortic lymph node
swelling, peritoneal dissemination, non-endometrioid histology,
clear cell histology and increased tumour markers (CA125, CA19-9
Thromboembolism in endometrial carcinoma
T Satoh et al
1035















sTable 1 Relative risks (ORs) of venous thromboembolism according to personal characteristics, tumour extension, direct invasion, histology and tumour
markers
Characteristics Incidence rate OR (95% CI) P-value
Age (years)
o60 6/103 (5.8%) Reference
X60 11/68 (16.2%) 3.12 (1.09–8.89) 0.03
Body mass index (kg/m
2)
o25 12/103 (11.7%) Reference
X25 5/68 (7.4%) 0.61 (0.20–1.79) 0.88
Smoking
Non-smoker 15/158 (36.8%) Reference
Smoker 2/13 (100%) 1.77 (0.35–8.57) 0.49
Menopause
No 4/38 (10.5%) Reference
Yes 13/133 (9.7%) 0.92 (0.28–3.01) 0.52
Parity
o3 11/131 (8.4%) Reference
X3 6/40 (15.0%) 1.93 (0.66–5.59) 0.18
Diabetes mellitus
No 13/144 (9.0%) Reference
Yes 4/27 (100%) 1.75 (0.53–5.85) 0.27
Anticoagulative medication for brain or heart disease
No 17/166 (10.2%) Reference
Yes 0/5 (0.0%) 0 1.00
Tumour size in uterine cavity (MRI) (mm)
o60 6/134 (4.5%) Reference
X60 11/26 (29.7%) 9.03 (3.06–26.6) o0.0001
Myometrial invasion (MRI)
p1/2 7/120 (5.8%) Reference
41/2 10/51 (19.6%) 3.94 (1.41–11.0) 0.009
Tumour extension (CT/MRI)
Localised to the uterus 3/120 (2.5%) Reference
Extrauterine spread 14/51 (27.5%) 14.8 (4.02–54.2) o0.0001
Plevic LN swelling 410mm (CT)
Absent 11/141 (7.8%) Reference
Present 6/30 (20.0%) 2.95 (0.997–8.75) 0.053
Paraaortic LN swelling 410mm (CT)
Absent 10/150 (6.7%) Reference
Present 7/21 (33.3%) 7.00 (2.30–21.3) 0.001
Massive ascites (CT)
a
Absent 14/165 (8.48%) Reference
Present 3/6 (50%) 10.8 (1.99–58.5) 0.01
Ovarian metastasis (MRI)
Absent 12/158 (7.6%) Reference
Present 5/13 (38.5%) 7.60 (2.15–26.9) 0.004
Peritoneal dissemination (CT)
Absent 10/154 (6.5%) Reference
Present 7/17 (53.9%) 10.1 (3.16–32.1) 0.0003
Distant metastasis except for peritoneal dissemination (CT or physical examination)
Absent 15/166 (9.0%) Reference
Present 2/5 (40.0%) 6.7 (1.04–43.4) 0.08
Histology
Endometrioid carcinoma 9/150 (6.0%) Reference
Non-endometrioid carcinoma 8/21 (38.1%) 9.64 (4.46–46.0) 0.0002
Serous carcinoma 3/9 (33.3%) 7.83 (1.68–36.6) 0.02
Clear cell carcinoma 4/6 (66.7%) 31.3 (5.05–195) 0.0004
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sand CEA) were significantly associated with VTE before treatment
in univariate analysis. Subsequently, we performed the multi-
variate analysis using several significant variables in the univariate
analysis. In the multivariate analysis, we focused on the following
four representative variables, because there were apparent
correlations among some variables (data not shown). ‘Tumour
extention (extrauterine spread)’ was selected out of various
significant variables representing tumour extension or metastasis
including tumour markers. Similarly, we selected ‘myometrial
invasion’ over ‘tumour size in the uterine cavity’ as a factor
representing direct invasion and ‘non-endometrioid histology’
over ‘clear cell histology’ as a factor representing histology.
Multivariate analysis for age, extrauterine spread, myometrial
invasion and non-endometrioid histology confirmed extrauterine
spread and non-endometrioid histology as independently and
significantly associated with the risk of VTE before treatment
(Table 2).
Management of VTE before treatment
Anticoagulant therapy using unfractionated heparin was adminis-
tered before initial treatment for all 17 patients with VTE and after
surgery for 14 patients who underwent primary or interval surgery.
Three patients underwent no surgery because two patients
displayed disease progression during NAC and the remaining
one patient had severe heart disease. In addition to anticoagulant
therapy, the placement of IVCF before upfront surgery was used
for one patient with floating DVT, and NAC was performed for five
patients. In summary, we managed patients with VTE before
treatment as follows: (1) anticoagulant therapy alone in 11
patients; (2) upfront surgery with placement of IVCF in 1 patient;
and (3) NAC followed by surgery in 5 patients.
VTE after commencement of treatment
None of the 17 patients with silent VTE before treatment developed
clinical manifestations of VTE after the commencement of
treatment, whereas 7 of the remaining 154 patients (4.6%)
developed VTE (DVT alone, n¼4; DVT plus PTE, n¼3), after
surgery in 3 patients and during chemotherapy in 4 patients. Of
these seven patients, four patients had asymptomatic VTE (DVT
alone, n¼3; DVT plus PTE, n¼1), and VTE was identified on
routine CT and subsequent PS after surgery or during chemo-
therapy. Three of the seven patients showed DD X1.5mgml
 1
before treatment, although DVT was not detected by VUI.
DISCUSSION
This study detected silent DVT and DVT plus PTE before
treatment in 9.9 and 4.7%, respectively, of patients with
endometrial cancer. These incidences appear lower than 25.0 and
11.1%, respectively, in ovarian cancer reported in our previous
paper (Satoh et al, 2007), although incidences in endometrial
cancer were higher than the 5.2 and 1.2% in cervical cancer,
respectively (unpublished data). As for DD level, 21.6% showed
levels X1.5mgml
 1 in endometrial cancer, suggesting a lower
percentage than the 63.9% in ovarian cancer and higher than the
14.5% in cervical cancer (unpublished data). However, several
studies have documented higher incidence of postoperative DVT
and PTE in endometrial cancer than in ovarian cancer (Clarke-
Pearson et al, 1983; Crandon and Koutts, 1983; Gore et al, 1984;
Suzuki et al, 2005). Incidence of silent VTE before surgery is
unlikely to account for the high incidence of VTE after surgery in
endometrial cancer.
Univariate and multivariate analyses revealed extrauterine
spread and non-endometrioid histology as independently and
significantly associated with the risk of VTE before treatment in
endometrial cancer. Many variables regarding advanced disease
were identified as significant risk factors for VTE before treatment
Table 1 (Continued)
Characteristics Incidence rate OR (95% CI) P-value
CA125 (ULN: 35Uml
 1)
p35 4/114 (3.5%) Reference
435 13/57 (22.8%) 8.13 (2.51–26.3) 0.0002
p70 6/133 (4.5%) Reference
470 11/38 (29.0%) 8.62 (2.93–25.3) o0.0001
CA19-9 (ULN:37Uml
 1)
p37 8/95 (8.4%) Reference
437 8/62 (50.0%) 1.61 (0.57–4.54) 0.26
p74 8/118 (6.8%) Reference
474 8/39 (20.5%) 3.55 (1.23–10.2) 0.02
CEA (ULN:5ngml
 1)
p5 11/132 (8.3%) Reference
45 6/23 (26.1%) 3.88 (1.27–11.9) 0.02
o10 14/147 (9.5%) Reference
X10 3/8 (37.5%) 5.70 (1.23–26.4) 0.04
95% CI¼95% confidence interval; LN¼lymphonode; OR¼odds ratio; ULN¼upper limits of normal.
aMassive ascites was defined as centralisation detected by CT in this
study.
Table 2 The multivariate analysis for the four representative risk factors
of venous thromboembolism
Characteristics VTE RR (95% CI) P-value
Age (years)
o60 6/103 (5.8%) Reference
X60 11/68 (16.2%) 1.82 (0.47–7.34) 0.38
Tumour extension (CT/MRI)
Localised to the uterus 3/120 (2.5%) Reference
Extrauterine spread 14/51 (27.5%) 14.4 (3.24–83.2) 0.001
Histology
Endometrioid carcinoma 9/150 (6.0%) Reference
Non-endometrioid carcinoma 8/21 (38.1%) 4.61 (1.20–18.0) 0.03
Myometrial invasion (MRI)
p1/2 7/120 (5.8%) Reference
41/2 10/51 (19.6%) 0.50 (0.13–2.52) 0.50
95% CI¼95% confidence interval; RR¼risk ratio; VTE¼venous thromboembolism.
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sin endometrial cancer, whereas our recent study revealed that
various risk factors regarding advanced disease other than massive
ascites were not significant risk factors for VTE before treatment in
ovarian cancer. As for VTE after surgery or during treatment, a
considerable number of previous reports have indicated advanced
disease as a significant risk factor for VTE in gynaecological
malignancies (Dubuc-Lissoir et al, 1999; Agnelli et al, 2006; Wang
et al, 2006).
Among non-endometrioid histologies, clear cell histology seems
to represent the highest risk factor (clear cell histology, 4 out of 6
(66.7%); non-clear cell histology, 4 out of 15 (26.7%)). We have
recently reported clear cell histology as a strong risk factor for VTE
before treatment in ovarian cancer (Satoh et al, 2007), and clear
cell carcinoma shows significantly stronger expression of tissue
factor, a major factor in the procoagulant activities of cancer cells,
as compared with non-clear cell carcinoma (Uno et al, 2007).
Several published reports support the association between clear
cell histology and VTE in ovarian cancer (Goff et al, 1996; Recio
et al, 1996). These reports have postulated that patients with clear
cell histology display a significantly higher incidence (11–42%) of
VTE as compared with those with non-clear cell histology in the
immediate postoperative period and during primary chemo-
therapy. Goff et al (1996) reported two ovarian cancer patients
with clear cell histology displaying DVT as a presenting symptom
before surgery. We have also reported an endometrial cancer
patient with clear cell histology showing VTE before treatment
(Toyoda et al, 2005). The same histology among different organs of
mullerian origin, such as the cervix, endometrium, ovaries and
fallopian tubes, is known to have some common genetic or
biological characteristics (Vang et al, 2001). The predisposition to
VTE might be one common biological characteristic of clear cell
histology in the endometrium and ovary.
Venous thromboembolism is one of the major postoperative
complications of endometrial cancer. Obesity, diabetes mellitus
and high oestrogen state, which often accompany endometrial
cancer, all represent risk factors for VTE (Ageno et al, 2008). In
addition, smoking, immobility, autoimmune disease, varicosity,
giant pelvic tumours, congestive cardiac failure and hyperlipidae-
mia are known risk factors for VTE after surgery. However, silent
VTE before treatment was not associated with obesity, smoking or
diabetes mellitus in this study (Table 1). In the univariate and
multivariate analyses of risk factors for VTE after the commence-
ment of treatment in 154 patients without VTE before treatment,
DD X1.5mgml
 1 before treatment, obesity (BMI 435kg/m
2) and
FIGO stage III/IV were all independent and significant risk factors
(data not shown). Advanced disease, extrauterine spread or FIGO
stage III/IV and DD X1.5mgml
 1 before treatment were risk
factors for VTE both before and after starting treatment, whereas
non-endometrioid histology was a risk factor for VTE before
treatment and obesity was a risk factor for VTE after starting
treatment.
In the guidelines for preventing VTE following general
surgery reported at the sixth American College of Chest Physicians
Consensus Conference (Greets et al, 2001), patients with
gynaecologic malignancies are classified as the highest risk group.
These guidelines focused on the prevention of postoperative
VTE and recommended the use of elastic stockings and
intermittent pneumatic compression during and after surgery,
and anticoagulant therapy after surgery in patients with gynaeco-
logic malignancies. However, this study and our recent study
revealed that patients may have silent or subclinical VTE even
before treatment in the presence of endometrial or ovarian
cancers. Given that VTE before treatment may represent the
highest risk for VTE after the commencement of treatment unless
special management is performed, preoperative assessment of VTE
may be important for reducing the incidence of VTE after starting
treatment.
In conclusion, the measurement of plasma DD level and
subsequent VUI revealed that silent or subclinical VTE occurs
before surgery in at least around 10% of patients with endometrial
cancer, although it might be presumed that if all patients had had
VUI, slightly more VTE would be found than reported here.
Detection of VTE before the treatment and management of VTE
may contribute to preventing postoperative VTE. However, VTE
can often occur after the commencement of treatment in
endometrial cancer patients without VTE before treatment,
particularly among those with risk factors such as DD
X1.5mgml
 1 before surgery, obesity, advanced stage or invasive
surgery. We recommend the assessment and management of VTE
before and after starting treatment of endometrial cancer as
follows: (1) measurement of DD level should be considered before
treatment in all patients. (2) Venous ultrasound imaging should be
performed before treatment in patients with DD X1.5mgml
 1. (3)
If VTE was found before cancer treatment, heparin treatment
should be started immediately. (4) For the prevention of VTE after
starting treatment, heparin should be used after surgery or during
chemotherapy at least for patients with DD X1.5mgml
 1 before
treatment, obesity or advanced stage in addition to patients with
VTE before treatment. Further clarification of the risk factors for
VTE before and after commencement of treatment is needed to
prevent VTE in endometrial cancer.
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